Syncona – building the next generation of global leaders in life science

Building a platform for long-term growth and impact

2024 annual report

Our purpose is to invest to extend and enhance human life

Watch video

Our team members are experts at what they do

Our people

A diversified portfolio of life science companies

Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

A diversified portfolio across clinical stages

Late-stage clinical companies

Late-stage clinical companies

Clinical companies

Clinical companies

Pre-clinical companies

Pre-clinical companies

Explore our portfolio

Introducing iOnctura

20.06.24 | Video length 5:52

Expansion of our senior team

16.01.24 | Video length 7:06

Launching Beacon Therapeutics

12.06.23 | Video length 7:36

Scaling for growth

12.12.22 | Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

28.04.22 | Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

03.11.21 | Video length 10:16

Anaveon doses first patient

24.06.21 | Video length 6:18

Introduction from Quell Therapeutics, CEO, Iain McGill

11.02.21 | Video length 5:38

Quell: the science and the unmet medical need for patients

11.02.21 | Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

11.02.21 | Video length 4:25

Introducing Resolution Therapeutics

02.12.20 | Video length 11:28

Introduction to Purespring

19.11.20 | Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

11.06.20 | Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

11.06.20 | Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

11.06.20 | Video length 2:53

Achilles doses first patient

29.05.20 | Video length 1:40

Gene Therapy explained

14.05.20 | Video length 3:11

Building Syncona’s Gene Therapy platform

23.10.19 | Video length 7:02

View all videos

04.09.24

A spotlight on our female leaders

20.06.24

Introducing iOnctura

27.02.24

Challenges continue but brighter days on the horizon

15.02.24

Navigating the biotech landscape: A journey from big pharma to innovative startups

25.01.24

Building a platform for the next generation of investors

16.01.24

Expansion of our senior team

08.08.23

Modality precision is the new precision in medicine

20.07.23

Taking a proactive approach to portfolio company sustainability

12.06.23

Launching Beacon Therapeutics

24.03.23

Leveraging the Syncona team for our next phase of growth

01.03.23

Good science must survive in challenging markets

12.12.22

Scaling for growth

Syncona

22.08.22

Building a global leader in retinal gene therapy

Gyroscope Therapeutics

13.07.22

Welcoming our first Windsor Fellowship intern to Syncona

28.04.22

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

03.11.21

Syncona CEO Martin Murphy discusses Clade Series A financing

Found, build, fund

24.09.21

Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships

17.09.21

Ed Hodgkin provides his perspectives from a career in early-stage biotech

Syncona

View all insights and articles

05.11.24

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

31.10.24

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)

30.10.24

Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

28.10.24

Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024

28.10.24

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

23.10.24

Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress

22.10.24

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses

16.10.24

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

15.10.24

Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

09.10.24

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

07.10.24

Mosaic Therapeutics appoints Dr Barry Davies as CSO

03.10.24

Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment

01.10.24

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024

01.10.24

OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2

19.09.24

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

19.09.24

Achilles Therapeutics Announces Strategic Update

19.09.24

Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP

27.08.24

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Investment team key facts

All as of 31 March 2024

12

Members of the investment team

150+

Years of life science and investment expertise

92%

Investment team with PhDs